房室结折返性心动过速的表型分型:机制见解与治疗意义
本研究对305例行导管消融和阿吉利丁激发试验的AVNRT患者进行两步聚类分析,基于17项人口学、临床、心电图及解剖变量,识别出3个临床和机制相关表型:代谢/结构性、结构性和解剖/遗传性表型。不同表型在发病年龄、合并症及消融结局上存在显著差异,提示AVNRT异质性高,个体化治疗需考虑共病与底物。
要点
- AVNRT分为3种表型,机制与临床结局不同。
- 代谢/结构性表型患者房颤及促心律失常风险更高。
- 表型分析有助于避免药物暴露并改善消融策略。
核心结论
- 表型分型识别出三种与临床和手术结局相关的AVNRT表型,强调共病与底物在AVNRT异质性中的重要性。
研究设计与样本
- 回顾性队列研究,纳入305例AVNRT患者,均行导管消融和阿吉利丁激发试验。
- 采用两步聚类分析,纳入17个变量,包括人口统计学、临床、心电图、超声心动图及解剖数据。
主要发现
- 识别出3个表型:代谢/结构性(n=44)、结构性(n=78)和解剖/遗传性(n=183)。
- 代谢/结构性表型患者AVNRT发病年龄更大(53.5±8.5岁 vs 43.5±15岁 vs 24.7±10.5岁),房室结距离更短(22.7±6.1 mm vs 24.7±6.8 mm vs 29±7.5 mm)。
- 该表型患者2型糖尿病(100% vs 0% vs 0%)和结构性心脏病(86.4% vs 100% vs 0%)比例更高。
关键数值与推荐
- 促心律失常发生率:代谢/结构性表型74.2%,结构性46.5%,解剖/遗传性31.6%(p=1.5×10^-4)。
- 电生理检查中AH延长/AV-VA阻滞:20.5% vs 7.7% vs 2.2%(p=8.9×10^-5)。
- 消融中止率:11.4% vs 1.3% vs 0%(p=8.6×10^-5)。
临床怎么用
- 术前识别表型有助于预测消融难度和复发风险。
- 代谢/结构性表型患者应警惕抗心律失常药物和非心脏药物的促心律失作用。
- 针对不同表型可能需调整消融策略和随访强度。
局限性
- 单中心研究,样本量有限,聚类分析基于回顾性数据。
- 未纳入长期随访结果,表型与远期复发的关系需进一步验证。
- 阿吉利丁激发试验结果未在文中详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AVNRT is a very heterogeneous entity caused by a variety of underlying conditions. Recognition of distinct clusters (phenotypes) may provide mechanistic insights, avoidance of exposure to proarrhythmic agents, and improvement of procedural outcomes and long-term recurrence. ABSTRACT Background Traditional classifications of atrioventricular nodal reentrant tachycardia (AVNRT) based on cardiac symptomatology, electrocardiographic findings, and reentrant circuits do not capture the full heterogeneity of AVNRT. Objective This study sought to identify distinct phenotypes among patients with AVNRT by using two-step cluster analysis and to determine differential effects of phenotypes on clinical and procedural outcomes. Methods All patients (n = 305) underwent catheter ablation and ajmaline challenge testing. A two-step cluster analysis was conducted using 17 demographic/clinical, anthropometric, electrocardiographic, echocardiographic, and anatomic variables. Results Three distinct clinically and mechanistically relevant clusters were identified. Cluster 1 (Metabolic/Structural Phenotype, n = 44) patients were characterized by older age of onset of AVNRT (53.5 ± 8.5, 43.5 ± 15, and 24.7 ± 10.5 years, p = 4.9 × 10−31), shorter distance between coronary sinus floor and His bundle potential (22.7 ± 6.1, 24.7 ± 6.8, and 29 ± 7.5 mm, p = 1.3 × 10−7), higher prevalence of “correlated” (diagnosed ≥ 4 years before AVNRT onset) type 2 diabetes (100%, 0%, and 0%, p = 5.9 × 10−67) and “correlated” (diagnosed ≥ 6 years before AVNRT onset) structural heart disease (86.4%, 100%, 0%, p = 3.5 × 10−62) compared to Cluster 2 (Structural Phenotype, n = 78) and Cluster 3 (Anatomic/Genetic Phenotype, n = 183) patients, respectively. Cluster 1 patients had higher prevalence of “pro-arrhythmia” (new-onset and/or symptom worsening/intolerance) with anti-arrhythmic therapy and/or non-cardiac drugs (74.2%, 46.5%, and 31.6%, p = 1.5 × 10−4), AH prolongation/AV-VA block (20.5%, 7.7%, and 2.2%, p = 8.9 × 10−5) and aborted ablation (11.4%, 1.3%, and 0%, p = 8.6 × 10−5) during EP study compared to Clusters 2 and 3 patients, respectively. Conclusion Phenomapping identified three clinically and mechanistically relevant phenotypes of AVNRT associated with clinical and procedural outcomes, underscoring the considerable heterogeneity of AVNRT and the importance of comorbidities and substrates.
引用
- Journal of Cardiovascular Electrophysiology:Phenomapping in Atrioventricular Nodal Reentrant Tachycardia: Mechanistic Insights and Therapeutic Implications
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。